Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study


SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date of 21 August 2020.

See the original post here:
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

Related Posts